Christopher Ryan Sullivan

All filings by Christopher Ryan Sullivan on record concern Avalo Therapeutics, Inc., in the capacity of senior executive. In total, 27 filings cover trades dated from 10 June 2020 to 16 September 2026.

On the open market, the record shows 4 purchases worth €18k and 11 sales worth €2.0M. The net balance comes to €2.0M on the selling side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 5 share grants and 7 option exercises. So far in 2026, the count stands at no purchases and 11 sales.

A typical purchase (the median) is worth €3,773. Clusters matter here: 4 out of 4 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The latest filing, published on 18 September 2026, reports an option exercise of €106k in Avalo Therapeutics, Inc. The last purchase on record was published on 13 June 2023, which is 1,229 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.